In 2019, the Institute for Clinical and Economic Review is planning to expand its cost effectiveness analyses in some high profile categories and assess treatments in a number of therapeutic areas it has not previously tackled, according to a recently-release list of proposed topics.
The list provides a preliminary look into the group’s current thinking about 2019, a spokesperson explained to the Pink Sheet....






